Home » Generex Begins Testing New Vaccine for Breast Cancer Patients
Generex Begins Testing New Vaccine for Breast Cancer Patients
April 29, 2005
Generex Biotechnology has announced that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the company's Phase I Trial.
The trial will include between 16 and 24 patients. The compound, AE37, is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct